Dyadic's C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations

Stock Information for Dyadic International Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dyadic International Inc.

Dyadic Announces Third Quarter 2026 Financial Results and Recent Developments
Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.
Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026
iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement 
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.